To our knowledge, there are no published studies that have directly investigated why normal cells are resistant to ClpP agonists or POLRMT inhibitors, although it has been speculated that cancer cells may have a greater demand for mitochondrial transcription to support an increased demand for OXPHOS [26,27,31]. The gene discussed is POLRMT; the disease is cancer.